Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting

The operating financial results of the Company’s R&D segment for the three and nine months ended September 30, 2025 and 2024 are as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Revenue	$	795	$	—	$	3,150	$	—
Less: Significant segment expenses
Personnel-related expenses	4,922		5,242		15,701		14,795
Clinical and preclinical expenses	4,313		4,589		13,502		13,283
Facilities-related and overhead	2,090		1,937		6,088		5,655
Professional and consulting fees	2,204		1,312		5,390		4,128
Corporate expenses	297		317		1,334		814
Impairment of right-of-use asset	494		—		494		—
Travel and entertainment	126		119		420		379
Plus: Other segment (loss) income	(1,448)		32		(340)		542
Segment net loss	$	(15,099)	$	(13,484)	$	(40,119)	$	(38,512)